Pertussis cost reduction through vaccination in Spain

Pertussis cost reduction through vaccination in Spain PharmacoEconomics & Outcomes News 804, p26 - 2 Jun 2018 Pertussis cost reduction through vaccination in Spain Children, aged 0–9 years with pertussis, have reduced mean direct healthcare costs following vaccination with 4–5 doses of acellular vaccines than their unvaccinated or partially vaccinated peer group, according to the findings of a study conducted in Catalonia (Spain). All children aged 0–9 years in Catalonia with pertussis detected by epidemiological surveillance between 1 January 2012 and 31 December 2013, and with validated vaccination status were included in the study (n = 579). Direct health costs comprising the expenditure for detection, treatment and chemoprophylaxis of contacts were calculated. Participants were classified as vaccinated (4–5 doses (45.3%)), partially vaccinated (1–3 doses (27.5%)) or unvaccinated (27.3%). The odds ratios were significantly lower in the vaccinated cohort for hospitalisation (OR 0.02, p < 0.001), severe disease (OR 0.02, p < 0.001) and laboratory based pertussis confirmation (OR 0.21, p < 0.001) than the unvaccinated or partially vaccinated children. Mean direct healthcare costs (based on resources used and prices in 2012–2013) were significantly lower (p < 0.001) in vaccinated patients than partially or unvaccinated patients at €190.6 (6.3% of total pertussis costs), €1116.9 (22.5%) and €3550.8 (71.2%) respectively. Multivariable linear regression analysis revealed that 4–5 doses of pertussis vaccine was associated with a non-significant reduction of €107.9/case after accounting for other study variables and €200/case after accounting for disease severity. "The results obtained in this study indicate that pertussis vaccination during childhood is one of the key pertussis prevention strategies to reduce the burden of pertussis and pertussis costs in individuals aged 0–9 years", concluded the authors. Plans-Rubio P, et al. Reduction of Direct Health Costs Associated with Pertussis Vaccination with Acellular Vaccines in Children Aged 0-9 Years with Pertussis in Catalonia (Spain). PharmacoEconomics-Open : 14 May 2018. Available from: URL: https://doi.org/10.1007/s41669-018-0081-4 803322890 1173-5503/18/0804-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Jun 2018 No. 804 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Pertussis cost reduction through vaccination in Spain

Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/pertussis-cost-reduction-through-vaccination-in-spain-Tbm0pY0i4x
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-018-4990-3
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 804, p26 - 2 Jun 2018 Pertussis cost reduction through vaccination in Spain Children, aged 0–9 years with pertussis, have reduced mean direct healthcare costs following vaccination with 4–5 doses of acellular vaccines than their unvaccinated or partially vaccinated peer group, according to the findings of a study conducted in Catalonia (Spain). All children aged 0–9 years in Catalonia with pertussis detected by epidemiological surveillance between 1 January 2012 and 31 December 2013, and with validated vaccination status were included in the study (n = 579). Direct health costs comprising the expenditure for detection, treatment and chemoprophylaxis of contacts were calculated. Participants were classified as vaccinated (4–5 doses (45.3%)), partially vaccinated (1–3 doses (27.5%)) or unvaccinated (27.3%). The odds ratios were significantly lower in the vaccinated cohort for hospitalisation (OR 0.02, p < 0.001), severe disease (OR 0.02, p < 0.001) and laboratory based pertussis confirmation (OR 0.21, p < 0.001) than the unvaccinated or partially vaccinated children. Mean direct healthcare costs (based on resources used and prices in 2012–2013) were significantly lower (p < 0.001) in vaccinated patients than partially or unvaccinated patients at €190.6 (6.3% of total pertussis costs), €1116.9 (22.5%) and €3550.8 (71.2%) respectively. Multivariable linear regression analysis revealed that 4–5 doses of pertussis vaccine was associated with a non-significant reduction of €107.9/case after accounting for other study variables and €200/case after accounting for disease severity. "The results obtained in this study indicate that pertussis vaccination during childhood is one of the key pertussis prevention strategies to reduce the burden of pertussis and pertussis costs in individuals aged 0–9 years", concluded the authors. Plans-Rubio P, et al. Reduction of Direct Health Costs Associated with Pertussis Vaccination with Acellular Vaccines in Children Aged 0-9 Years with Pertussis in Catalonia (Spain). PharmacoEconomics-Open : 14 May 2018. Available from: URL: https://doi.org/10.1007/s41669-018-0081-4 803322890 1173-5503/18/0804-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Jun 2018 No. 804

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Jun 2, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off